Urcosimod Phase 2a Trial Shows Meaningful QoL Improvements in Neuropathic Corneal Pain
summarizeSummary
OKYO Pharma announced new positive exploratory Phase 2a data for its drug candidate, Urcosimod, in treating neuropathic corneal pain (NCP). The data demonstrated meaningful improvements in patient-reported quality of life (QoL) outcomes, including emotional well-being and daily life satisfaction, compared to placebo. This builds on previously reported primary efficacy signals (pain reduction) from the same small Phase 2a trial. NCP is a severe condition with no FDA-approved treatments, representing a significant unmet medical need. While the data is from an exploratory analysis of a small trial (n=6 per arm), these positive QoL findings, alongside pain reduction, suggest a broader therapeutic profile for Urcosimod and strengthen the case for its advancement. The company plans confirmatory studies, including a larger multi-center Phase 2b/3 trial, which will be critical for validating these encouraging early results.
At the time of this announcement, OKYO was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82.2M. The 52-week trading range was $1.03 to $3.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.